Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
06. Juli 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
21. Juni 2022 07:12 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
10. Mai 2022 08:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical...
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
22. Februar 2022 07:15 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
31. Januar 2022 08:00 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors. Dr....
Zenith 與 Newsoara Biopharma 宣佈擴大許可協議和投資
16. November 2021 06:58 ET
|
Zenith Capital Corp.
亞伯達省卡加利, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp.（「Zenith」或「公司」）今天宣佈 Zenith Capital 全資子公司 Zenith Epigenetics Ltd.（「Zenith Epigenetics」）剛與 Newsoara Biopharma Co., Ltd.（「Newsoara」）就...
Zenith和Newsoara Biopharma宣布扩展许可和投资
16. November 2021 06:58 ET
|
Zenith Capital Corp.
阿尔伯塔省卡尔加里, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp.（以下简称“Zenith”）今日宣布，Zenith Capital的全资子公司Zenith Epigenetics Ltd.（以下简称“Zenith Epigenetics”）已与Newsoara Biopharma Co.,...
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
15. November 2021 09:55 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of...
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
21. September 2021 08:00 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients
17. August 2021 08:00 ET
|
Zenith Capital Corp.
CALGARY, Alberta, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic...